<?xml version="1.0" encoding="UTF-8"?>
<p>To prove biosimilarity between the 2 filgrastim products, ANC and CD34
 <sup>+</sup> cell counts were evaluated as well as plasma drug concentration measurements.
 <xref rid="b14-dddt-12-2381" ref-type="bibr">14</xref>,
 <xref rid="b19-dddt-12-2381" ref-type="bibr">19</xref> On PK evaluation, the 90% CIs of the test to reference ratios for the primary assessment parameters (
 <italic>C</italic>
 <sub>max</sub> and AUC
 <sub>0–∞</sub>) were within 80%–125%, suggesting that a sufficient similarity exists between the 2 products. In PD evaluation, 
 <italic>E</italic>
 <sub>max</sub> and AUEC
 <sub>0–last</sub> for ANC were primary assessment parameters, and the 90% CIs were also within 0.8–1.25 range. Although one of the secondary assessment parameters of PD, the 90% CI for 
 <italic>E</italic>
 <sub>max</sub> of CD34
 <sup>+</sup> cell counts, at 5 μg/kg dose fell outside 0.8–1.25 range, the other CIs were within the ranges that satisfy biosimilarity. The overall effect-time profiles between the 2 products could be considered comparable.
</p>
